Pharma Outside the Fray As Obama Re-Evaluates Bush’s Pre-emption Policy
This article was originally published in The Tan Sheet
Executive Summary
The good news for drug firms about President Obama's memo curtailing federal pre-emption state laws: It will not have any real impact on industry. The bad news: It will not matter because pre-emption in the drug arena already took a body blow in the Supreme Court's Wyeth v. Levine ruling
You may also be interested in...
On Pre-emption, OTC Rule Among Signs Tipping Obama Administration’s Hand
FDA has not altered its support of pre-emption in product liability suits but there are signs it will happen under the Obama administration
High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo
The Supreme Court's ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from state product liability lawsuits, but is not expected to trigger a sea-change in current industry operations
Supreme Court Ties On FDA Pre-Emption; Congress Seeks To Resolve Issue
Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval